• 2025.12.16Timely Disclosure
  Announcement of initiation of an investigator-initiated clinical trial with a PAI-1 inhibitor RS5614 in combination with gemcitabine and nab-paclitaxel for treatment of patients with unresectable or recurrent metastatic pancreatic cancer(262KB)
• 2025.12.15Timely Disclosure
  Announcement of initiation of a Phase III bridging study for unresectable melanoma in Taiwan(270KB)
• 2025.12.12Timely Disclosure
  Announce Completion of Patient Enrollment for Cutaneous Angiosarcoma Treatment(151KB)
• 2025.12.01Others
  Announcement of an Interview Article Related to Our Company in Nature (Digital edition)(138KB)
• 2025.11.26Timely Disclosure
  Announcement of the Initiation of a Phase II Investigator-Initiated Clinical Trial of a PAI-1 Inhibitor (RS5614) Combination Therapy in Chemoradiotherapy and Immune Checkpoint Inhibitor Consolidation Therapy (First-Line Treatment) for Locally Advanced Non-Small Cell Lung Cancer(260KB)

IR News List